CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.800
0.00 (0.00%)
Aug 5, 2026, 10:10 AM EDT - Market open
CervoMed Stock Forecast
CRVO's stock price has decreased by -70.2% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 7 analysts polled by S&P Global, CervoMed stock has a consensus rating of "Strong Buy" and an average price target of $19.5. The average 1-year stock price forecast is 596.43% higher than the current stock price, while the lowest is $9.00 (+221.43%) and the highest is $27 (+864.29%).
Price Target: $19.5 (+596.43%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CervoMed stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +792.86% | Aug 5, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $9 | Buy | Reiterates | $9 | +221.43% | Jun 11, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $27 | Buy | Reiterates | $27 | +864.29% | May 19, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $20 | Buy | Maintains | $20 | +614.29% | May 19, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +650.00% | May 18, 2026 |
Financial Forecast
Revenue This Year
266.67K
from 4.01M
Decreased by -93.34%
Revenue Next Year
833.33K
from 266.67K
Increased by 212.49%
EPS This Year
-2.77
from -2.98
EPS Next Year
-2.51
from -2.77
EPS and Forward PE are based on non-GAAP adjusted numbers.